What is BioRestorative Therapies, Inc. (BRTX)?

BioRestorative Therapies, Inc. (BRTX) is a stock in the Healthcare sector, Biotechnology industry. View full analysis on Stocks360.

What is the current price of BRTX?

The current price of BRTX is $1.39. Prices are updated in real time on Stocks360.

What is BRTX's price-to-earnings (PE) ratio?

BRTX's trailing twelve-month PE ratio is -0.06, based on current price and earnings per share data available on Stocks360.

What is BRTX's market capitalization?

BRTX's market capitalization is $1,919,768.00, placing it in the small-cap tier.

BioRestorative Therapies, Inc. (BRTX)

Stock analysis · NASDAQ · Healthcare · Biotechnology

$1.39

Market Cap

$1.92M

PE (TTM)

-0.06

EPS (TTM)

N/A

Dividend Yield

0.00%

Beta

0.74

Day Range

$1.38 – $1.47

52-wk Range

$1.28 – $33.80

Avg Volume

N/A

Volume

17.26K

BioRestorative Therapies, Inc. (BRTX) is a publicly traded company in the Healthcare sector. Latest price: $1.39. Market cap $1.92M. Trailing PE -0.06. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.

Get full analysis → Short-Term Analysis →

1-Year Price

2025-10-29 · $31.20 2026-10-28 · $1.39 (-95.54%)

Earnings

Most Recent

May 13, 2026

EPS $-0.24 vs est. $-6.00

Beat by $5.76

Next Earnings

Nov 11, 2026

EPS estimate $-1.40

Proprietary Signals

Signal snapshot temporarily unavailable.

About BioRestorative Therapies, Inc.

BioRestorative Therapies, Inc. is a life sciences company dedicated to developing regenerative medicine products and therapies. Their approach primarily utilizes adult stem cell protocols to address two key areas: disc/spine disease and metabolic disorders. Within their disc/spine program, known as brtxDisc, the company's leading cell therapy candidate is BRTX-100. This treatment involves culturing mesenchymal stem cells harvested from a patient's own bone marrow (autologous) to provide a non-surgical solution for painful lumbosacral disc conditions. BRTX-100 has successfully completed Phase 1 clinical trials. The company is also advancing its Metabolic Program, named ThermoStem, which is currently in the preclinical stage. This cell-based therapy targets obesity and other metabolic ailments by employing brown adipose-derived stem cells to generate brown adipose tissue. Beyond these core programs, BioRestorative Therapies also offers an investigational curved needle device designed for delivering cells and various therapeutic materials to the spine and discs. The company fosters strategic research and development partnerships, including agreements with Rohto Pharmaceutical Co., Lt…

Valuation

Trailing twelve months. Multiples relative to current market price.
P/E (TTM)	-0.06×
P/S (TTM)	5.36×
P/B	0.41×
P/FCF (TTM)	-0.16×
EV / EBITDA	0.11×
EV / Sales	-3.24×
Earnings Yield	-897.39%
Free Cash Flow Yield	-619.74%

Fundamentals

Trailing twelve months. Source: financial statements via market data.
Enterprise Value	-$1.16M
Net Income (TTM)	-$17.23M
Free Cash Flow (TTM)	-$11.90M
Net Debt	-$3.08M
Working Capital	$2.19M
Gross Margin	92.09%
Operating Margin	-3975.00%
Net Margin	-3089.55%
Return on Equity	-423.84%
Return on Invested Capital	-464.86%